| Predicted Trait | |
| Reported Trait | Psoriasis |
| Mapped Trait(s) | psoriasis (EFO_0000676) |
| Additional Trait Information | Score was developed using GWAS of psoriasis susceptibility and tested on prediction of severe psoriasis (vs. non-severe disease) |
| Score Construction | |
| PGS Name | Full_subset |
| Development Method | |
| Name | SBayesR |
| Parameters | SNPs in high LD removed (R2 > 0.9, SNP with lowest susceptibility P-value was retained). Otherwise standard SBayesR arguments. Variants filtered to only those in study datasets (Estonian Biobank, FinnGen, HUNT, UK Biobank, BSTOP, Novartis). |
| Variants | |
| Original Genome Build | hg19 |
| Number of Variants | 487,311 |
| Effect Weight Type | beta |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000760 |
| Citation (link to publication) | Saklatvala JR et al. Genome Med (2025) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 52,950 individuals (100%) |
| PGS Evaluation | European: 100% 2 Sample Sets |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
| — | [
|
European | CASP, Genizon, KIEL, UCSF, WTCCC |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM023031 | PSS012093| European Ancestry| 13,577 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis (BSTOP) vs. any psoriasis (UKB) | — | — | Percentage of cases with risk >95th percentile of UKB psoraisis cases: 15.3 | — | — |
| PPM023033 | PSS012097| European Ancestry| 10,887 individuals |
PGP000760 | Saklatvala JR et al. Genome Med (2025) |
Reported Trait: Severe psoriasis (Novartis) vs. any psoriasis (UKB) | — | — | Percentage of cases with risk >95th percentile of UKB psoraisis cases: 11.6 | — | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS012097 | — | — | 1,461 individuals | — | European | — | Novartis | 1,461 in Novartis is compared against 9426 UKB |
| PSS012097 | — | — | 9,426 individuals | — | European | — | UKB | 1,461 in Novartis is compared against 9426 UKB |
| PSS012093 | — | — | 4,151 individuals | — | European | — | BSTOP | 4,151 in BSTOP is compared against 9426 UKB |
| PSS012093 | — | — | 9,426 individuals | — | European | — | UKB | 4,151 in BSTOP is compared against 9426 UKB |